Open Access Articles- Top Results for Reverse pharmacology

Reverse pharmacology

This article is about hypothesis driven drug discovery. For Ashok Vaidya's clinical trial method, see Classical pharmacology#Application to Ayurvedic drugs.

In the field of drug discovery, reverse pharmacology [1][2][3] also known as target base drug discovery (TDD),[4] a hypothesis is first made that modulation of the activity of a specific protein target will have beneficial therapeutic effects. Screening of chemical libraries of small molecules is then used to identify compounds that bind with high affinity to the target. The hits from these screens are then used as starting points for drug discovery. This method became popular after the sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins. This method is the most widely used in drug discovery today.[5]

See also


  1. ^ Takenaka T (September 2001). "Classical vs reverse pharmacology in drug discovery". BJU Int. 88 Suppl 2: 7–10; discussion 49–50. PMID 11589663. doi:10.1111/j.1464-410X.2001.00112.x. 
  2. ^ Lazo JS (April 2008). "Rear-view mirrors and crystal balls: a brief reflection on drug discovery". Mol. Interv. 8 (2): 60–3. PMID 18403648. doi:10.1124/mi.8.2.1. 
  3. ^ Bachmann KA, Hacker MP, Messer W (2009). Pharmacology principles and practice. Amsterdam: Elsevier/Academic Press. p. 576. ISBN 0-12-369521-X. 
  4. ^ Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ (May 2012). "Modern phenotypic drug discovery is a viable, neoclassic pharma strategy". J. Med. Chem. 55 (10): 4527–38. PMID 22409666. doi:10.1021/jm201649s. 
  5. ^ Swinney DC, Anthony J (July 2011). "How were new medicines discovered?". Nat Rev Drug Discov 10 (7): 507–19. PMID 21701501. doi:10.1038/nrd3480. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.